BIOMAT Database Logo BIOMAT Database Logo

L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial. 2020

Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Mental Health Research Center, Iran University of Medical Sciences, Tehran, Iran.

Evidence for antidepressant effects of L-Carnosine was shown in some experimental studies. In this study we tried to evaluate the efficacy and tolerability of L-Carnosine combination therapy in treatment of patients with major depressive disorder (MDD). Fifty-eight patients with MDD (DSM-V) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 400 mg twice daily L-Carnosine or placebo in addition to citalopram (maximum dosage of 40 mg/day) for six weeks in a randomized double-blind, and placebo-controlled study. Patients were assessed using the HAM-D scale at baseline and weeks 2, 4, and 6. Fifty-two patients completed the trial. General linear model repeated measure showed significant difference for time × treatment on HAM-D score [F = 3.17, df = 2.39, p-value = 0.03]. Significantly greater improvement was detected in HAM-D score of the L-Carnosine group compared with the placebo group from baseline to weeks 2, 4 and 6 [Ps = 0.013, 0.028 and 0.023; respectively]. Patients in the L-Carnosine group experienced significantly greater response and remission rate than the placebo group [Ps = 0.023 and 0.012; respectively]. There was no significant difference between the two groups in baseline parameters and frequency of side effects. Short follow-up period and small population size were two important limitations of this study. L-Carnosine combination therapy with citalopram can effectively improve symptoms of patients with major depressive disorder. Rapid-onset antidepressant effects of L-Carnosine were also shown which need further investigation.

UI MeSH Term Description Entries
D002336 Carnosine A naturally occurring dipeptide neuropeptide found in muscles. Carnosine Hydrochloride,Carnosine, (D-His)-Isomer,L-Carnosine,beta-Alanylhistidine,Hydrochloride, Carnosine,L Carnosine,beta Alanylhistidine
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D015283 Citalopram A furancarbonitrile that is one of the SELECTIVE SEROTONIN REUPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia. Celexa,Citalopram Hydrobromide,Cytalopram,Lu-10-171,Seropram,Lu10171
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
January 2017, Clinical neuropharmacology,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial.
April 2016, Journal of psychiatric research,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
l-theanine adjunct to sertraline for major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial.
July 2023, Journal of affective disorders,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
May 2021, International clinical psychopharmacology,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.
August 2012, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Rhodiola rosea therapy for major depressive disorder: a study protocol for a randomized, double-blind, placebo- controlled trial.
June 2014, Journal of clinical trials,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.
May 2018, Journal of affective disorders,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
April 2002, The Journal of clinical psychiatry,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
June 2018, Psychopharmacology bulletin,
Behin Araminia, and Mohammadreza Shalbafan, and Amirhosein Mortezaei, and Elham Shirazi, and Salomeh Ghaffari, and Erfan Sahebolzamani, and Seyyed Hosein Mortazavi, and Behnam Shariati, and Mehrdad Eftekhar Ardebili, and Ali Aqamolaei, and Sina Naderi, and Shahin Akhondzadeh
l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
February 2018, Journal of child and adolescent psychopharmacology,
Copied contents to your clipboard!